116312-69-7

Usage

Uses

Used in Organic Synthesis:
1-(TETRAHYDRO-2H-PYRAN-4-YL)HYDRAZINE HYDROCHLORIDE is used as a reagent for the preparation of various organic compounds, leveraging its unique chemical structure to facilitate the synthesis process.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 1-(TETRAHYDRO-2H-PYRAN-4-YL)HYDRAZINE HYDROCHLORIDE is used as a key intermediate in the development of new drugs. Its properties make it a valuable component in the creation of pharmaceutical agents with potential therapeutic applications.
Used in Agrochemical Development:
Similarly, in agrochemical research, 1-(TETRAHYDRO-2H-PYRAN-4-YL)HYDRAZINE HYDROCHLORIDE is employed as a reagent in the synthesis of agrochemicals, contributing to the development of new products for agricultural use.
Overall, 1-(TETRAHYDRO-2H-PYRAN-4-YL)HYDRAZINE HYDROCHLORIDE's versatility in different chemical reactions and its enhanced solubility and stability due to its hydrochloride salt form make it a valuable asset across various scientific and industrial applications.

InChI:InChI=1/C5H12N2O/c6-7-5-1-3-8-4-2-5/h5,7H,1-4,6H2

Upstream product

• 97986-34-0 toluene-4-sulfonic acid tetrahydropyran-4-yl ester 
• 134419-59-3 4-oxanyl methanesulfonate 
• 693287-78-4 N’-(tetrahydropyran-4-ylidene)hydrazinecarboxylic acid tert-butyl ester 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 693287-79-5 N’-(tetrahydropyran-4-yl)hydrazinecarboxylic acid tert-butyl ester 

Downstream Products

• 1082745-50-3 5-amino-1-(tetrahydropyran-4-yl)-1H-pyrazole-4-carboxylic acid amide 
• 1247075-24-6 3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-5-amine 
• 950859-30-0 ethyl 5-amino-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole-4-carboxylate 

Relevant academic research and scientific papers

Discovery, synthesis and characterization of a series of (1-alkyl-3-methyl-1H-pyrazol-5-yl)-2-(5-aryl-2H-tetrazol-2-yl)acetamides as novel GIRK1/2 potassium channel activators

The present study describes the discovery and characterization of a series of 5-aryl-2H-tetrazol-3-ylacetamides as G protein-gated inwardly-rectifying potassium (GIRK) channels activators. Working from an initial hit discovered during a high-throughput screening campaign, we identified a tetrazole scaffold that shifts away from the previously reported urea-based scaffolds while remaining effective GIRK1/2 channel activators. In addition, we evaluated the compounds in Tier 1 DMPK assays and have identified a (3-methyl-1H-pyrazol-1-yl)tetrahydrothiophene-1,1-dioxide head group that imparts interesting and unexpected microsomal stability compared to previously-reported pyrazole head groups.

PYRAZOLOPYRIMIDINES AS INHIBITORS OF GLUCOCORTICOID RECEPTOR TRANSLOCATION

Provided herein are compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of Glucocorticoid Receptor (GR) translocation. Furthermore, the subject compounds and compositions are useful for the treatment of diseases involved in the hypothalamic-pituitary-adrenal (HPA) axis.

AZAINDAZOLES

Herein are disclosed azaindazoles of formula (I), (I), where the various groups are defined herein, and which are useful for treating cancer.

PI3K (DELTA) SELECTIVE INHIBITORS

Novel PI3K, especially PI3K delta isoform, selective inhibitors are disclosed. The compounds are useful in treating disorders related to abnormal PI3K or PI3Kδ activities such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders.

PI3K/MTOR KINASE INHIBITORS

6-morpholin-4-yl-pyrazolo[3,4-d]pyrimidine and 2-morpholin-4-yl-7H- pyrrolo[2,3-d]pyrimidine derivatives have unexpected drug properties as inhibitors of PI3 and/or mTOR kinases and are useful in treating disorders related to abnormal PI3K/mT0R activities such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders.

THIAZOLYL-DIHYDRO-INDAZOLES

The present invention encompasses compounds of general formula (1) wherein R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a

AMINO-HETEROCYCLIC COMPOUNDS

The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R, R1, R2 and R3 are as defined herein. Pharmaceutical compositions containing the compounds of Formul

PROCESS FOR PRODUCTION OF 4-AMINOTETRAHYDROPYRANS AND SALTS THEREOF WITH ACIDS, INTERMEDIATES FOR THE PROCESS, AND PROCESS FOR PRODUCTION THEREOF

The present invention relates to a process for preparing 4-aminotetrahydropyran compound and an acid salt thereof represented by the formula (2): wherein R represents a hydrogen atom or a hydrocarbon group, which comprises subjecting a 4-hydrazinotetrahydropyran compound or an acid salt thereof represented by the formula (1) : wherein R has the same meaning as defined above, to decomposition reaction in the presence of at least one compound selected from Raney nickel, noble metal catalyst and metal oxide, and a synthetic intermediate thereof and a process for preparing the same.

Synthesis and Selective Cyclooxygenase-2 Inhibitory Activity of a Series of Novel, Nitric Oxide Donor-Containing Pyrazoles

The synthesis of a series of novel pyrazoles containing a nitrate (ONO 2) moiety as a nitric oxide (NO)-donor functionality is reported. Their COX-1 and COX-2 inhibitory activities in human whole blood are profiled. Our data demonstrate that py